Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma
Woman and Man Max 99 years
Astellas Pharma Global Development, Inc (APGD)
Update Il y a 4 ans
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
To determine objective response rate (ORR) (complete remission [CR] + partial remission [PR]) per [the International Working Group (IWG) Revised Response Criteria for Malignant Lymphomas (2007)].
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Global Development, Inc
Update Il y a 4 ans
An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR Study) Estudio de Fase 3, abierto y aleatorizado, de la eficacia de ASP8273 frente a erlotinib o gefitinib como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico y mutaciones de activación del EGFR, en estadío IIIB/IV (Estudio SOLAR)
To evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectab...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity
To assess the efficacy of solifenacin 10mg compared to placebo in patients with neurogenic detrusor overactivity
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Global Development, Inc (APGD)
Update Il y a 4 ans
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis
To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile
The primary objective of the study is to investigate the plasma pharmacokinetics (PK) of fidaxomicin and primary metabolite OP-1118 in Subjects with Inflammatory Bowel Disease (IBD) and C. difficile I...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
Studying kidney function in patients with a kidney transplant treated with anti-rejection therapy based on Advagraf when used with or without sirolimus
To compare the effect two immunosuppressive therapy regimens on Glomerular Filtration Rate (GFR) estimated by Iohexol clearance at Week 52 post kidney transplantation. Arm 1: Advagraf® + MMF + Steroi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 4 ans
Étude MORPHO : étude de phase 3 randomisée visant à évaluer l’efficacité du giltéritinib comme traitement d’entretien après une greffe allogénique chez des patients ayant une leucémie myéloïde aiguë avec FLT3/ITD.
La leucémie myéloïde aiguë résulte de mutations acquises dans l’ADN d’une cellule de la moelle osseuse en développement. Cette cellule devient leucémique et se multiplie de façon incontrôlée, donnant ...
Country
France
organs
Leucémies aiguës
Specialty
Greffe
,
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 4 ans
ASTELLAS 2008002 : Essai de phase 2 randomisé évaluant l’efficacité et la tolérance d’un traitement associant le AGS-1C4D4 à de la gemcitabine, chez des patients ayant un cancer du pancréas métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité d’un traitement associant un anticorps (AGS-1C4D4) à la gemcitabine, chez des patients ayant un cancer du pancréas métastatique. Les patients seront...
Country
France
organs
Pancréas
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A study in which two antibiotics (vancomycin and fidaxomicin) are compared in older patients with infections of the gut caused by bacteria called Clostridium difficile
The primary objective of the study is to evaluate whether the extended duration fidaxomicin therapy is superior to the standard vancomycin therapy in sustained clinical cure of CDI at 30 days after en...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder
To assess the safety and tolerability of long-term treatment with YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next